Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis

Simona Leoni, Francesco Tovoli, Lucia Napoli, Ilaria Serio, Silvia Ferri, Luigi Bolondi

Abstract

The current epidemic of non-alcoholic fatty liver disease (NAFLD) is reshaping the field of hepatology all around the world. The widespread diffusion of metabolic risk factors such as obesity, type2-diabetes mellitus, and dyslipidemia has led to a worldwide diffusion of NAFLD. In parallel to the increased availability of effective anti-viral agents, NAFLD is rapidly becoming the most common cause of chronic liver disease in Western Countries, and a similar trend is expected in Eastern Countries in the next years. This epidemic and its consequences have prompted experts from all over the world in identifying effective strategies for the diagnosis, management, and treatment of NAFLD. Different scientific societies from Europe, America, and Asia-Pacific regions have proposed guidelines based on the most recent evidence about NAFLD. These guidelines are consistent with the key elements in the management of NAFLD, but still, show significant difference about some critical points. We reviewed the current literature in English language to identify the most recent scientific guidelines about NAFLD with the aim to find and critically analyse the main differences. We distinguished guidelines from 5 different scientific societies whose reputation is worldwide recognised and who are representative of the clinical practice in different geographical regions. Differences were noted in: the definition of NAFLD, the opportunity of NAFLD screening in high-risk patients, the non-invasive test proposed for the diagnosis of NAFLD and the identification of NAFLD patients with advanced fibrosis, in the follow-up protocols and, finally, in the treatment strategy (especially in the proposed pharmacological management). These difference have been discussed in the light of the possible evolution of the scenario of
NAFLD in the next years.

Key words: Non-alcoholic fatty liver disease; Metformin; Liver steatosis; Liver biopsy; Non-invasive diagnosis; Pioglitazone; Clinical guidelines

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Non-alcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease. As such, an increasing number of scientific reports are investigating this condition. To translate these evidence into clinical practice, international scientific societies have proposed guidelines for the management of NAFLD. In this review, we will critically analyse both the converging and diverging points in the current clinical guidelines of NAFLD, with a particular focus on the diagnostic and therapeutic aspects.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of disorders ranging from the simple fatty liver to non-alcoholic steatohepatitis, with increasing fibrosis leading to cirrhosis\(^1\). The prevalence of NAFLD is alarmingly growing worldwide in adult and children/adolescent populations, with a bidirectional association between NAFLD and metabolic syndrome\(^2\). Obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia are the most relevant metabolic conditions related to this spectrum of diseases\(^1,2\).

Clinicians and researchers from several scientific associations worldwide have put significant efforts into increasing knowledge and developing high-quality International Guidelines to improve the management of NAFLD patients in clinical practice. Multidisciplinary panels of experts in different continents have performed systematic analysis and review of the literature on specified topics in the last years. These efforts have led to the creation and publication of various Guidelines.

This paper aims to review and compare the most recently published International Guidelines for the diagnosis and the management of NAFLD in adult populations, to critically evaluate similarities and discrepancies. In particular, we tried to analyse some critical questions and challenges for clinicians in real life.

LITERATURE SEARCH

We performed a database search on PubMed selecting papers published between January 2016 and January 2018 in the English language. The following keywords and terms were considered: (1) Fatty liver disease ("fatty liver"[MeSH Terms] OR "fatty"[All Fields] AND "liver"[All Fields]) OR "fatty liver"[All Fields]) AND ("disease"[MeSH Terms] OR "disease"[All Fields]) AND guideline ("guideline"[Publication Type] OR "guidelines as topic"[MeSH Terms] OR "guideline"[All Fields]) AND management ("organization and administration"[MeSH Terms] OR ("organization"[All Fields] AND "administration"[All Fields]) OR "organization and administration"[All Fields] OR "management"[All Fields] OR "disease management"[MeSH Terms] OR ("disease"[All Fields] AND "management"[All Fields]) OR "disease management"[All Fields])); (2) Fatty liver disease AND recommendation ("fatty liver"[MeSH Terms] OR ("fatty"[All Fields] AND "liver"[All Fields]) OR "fatty liver"[All Fields]) AND ("disease"[MeSH Terms] OR "disease"[All Fields]) AND recommendation[All Fields]; (3) Fatty liver disease and position paper ("fatty liver"[MeSH Terms] OR ("fatty"[All Fields] AND "liver"[All Fields]) OR "fatty liver"[All Fields]) AND ("disease"[MeSH Terms] OR "disease"[All Fields]) AND (position[All Fields] AND ("paper"[MeSH Terms] OR "paper"[All Fields]))

According to this criteria, 119 papers were identified. As a second step, we excluded papers which were not pertinent to any of the following criteria: (1) Clinical Guidelines related to diagnosis and management of NAFLD in the adult population; (2) clinical Guidelines published by Governmental agencies and Scientific Associations.

According to the selection criteria, out of 119 results of PubMed research, 5 Guidelines were finally included in this analysis. These guidelines are strictly focused on the topic of diagnosis and management of NAFLD in adult, excluding pediatric populations and special groups. In detail, the five selected papers included (from the oldest to the newest date of publication): (1) “EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease” by the European Association for the Study of the Liver (EASL), published in 2016\(^3\); (2) “Nonalcoholic fatty liver disease (NAFLD): Assessment and management” by the National Institute for Health and Care Excellence (NICE), published in 2016\(^4\); (3) “Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease guidelines” published in 2017\(^5,6\); (4) Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions, published in 2017\(^7\); (5) “The diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases” published in 2018\(^8\).

OPEN QUESTIONS

Definition, classification, and diagnostic criteria of NAFLD

Definition and classification: A definition of NAFLD
The characteristic points of NAFLD definition include (1) the evidence of excessive hepatic fat accumulation in the liver parenchyma (detected by imaging techniques or histology); (2) the absence of other secondary causes of hepatic fat. Out of them, to strictly define NAFLD patients a significant ongoing or recent alcohol consumption have to be excluded in all recommendations [3–8].

All recommendations identify some different clinical-pathological entities, according to the progression of hepatic histological changes. Simple steatosis and non-alcoholic steatohepatitis (NASH) are defined in all guidelines [3–8]. In detail simple steatosis, also called non-alcoholic fatty liver (NAFL) includes all of the case characterized by steatosis with minimal or absent lobular inflammation. On the contrary, NASH is characterized by hepatocyte ballooning degeneration, diffused lobular inflammation and fibrosis (Figure 1).

Diagnostic criteria: The role of alcohol: The agreement between the different guidelines is not complete when defining the threshold dose of alcohol consumption. As shown in Table 1, EASL [3], NICE, and AISF guidelines [3,4,7] consider as significant an alcohol consumption > 30 g/d in men and > 20 g/d in women. The AASLD guidance [8] indicate the reasonable threshold for significant alcohol consumption > 21 standard drink on average per week in men and > 14 in women. For Asia-Pacific Guidelines [5] a significant alcohol intake was considered > 7 standard alcoholic drinks/week (70 g ethanol) in women and > 14 (140 g) in men.

Who should be screened for NAFLD? According to the screening programs adopted for other diseases, systematic screening has to be performed for significant health problem with available diagnostic facilities and accepted treatment. Also, there should be recognisable latent or early symptomatic stage, identifiable with sensitive tests. To adequately perform a screening program, the natural history of the disease should be understood, and the economic burden should...
be suitable.

The international guidelines partially diverge about this topic. This disagreement derives from essential considerations regarding natural history, special groups, diagnosis, and therapy: (1) NAFLD in a common cause of chronic liver disease in general population but cause severe liver disease in a small proportion of affected people[3]; (2) Type II diabetes patients have higher prevalence of NAFLD, NASH and advanced fibrosis[11-13]; (3) There is a current lack of effective drug treatment; (4) Liver biopsy is a procedure with related risks; (6) Few cost-effective analysis are available[14].

All these considerations imply a different approach to screening in NAFLD by the Scientific Societies. Only EASL, NICE Asia-Pacific Guidelines[3-5] recommend screening respectively in particular, “high-risk” groups (Table 2). On the contrary, AASLD guidelines emphasise that, to date, there is no evidence of cost-effectiveness to support a NAFLD screening in adults even if they have several metabolic risk factors, instead suggesting a concept of “vigilance” in these populations[3].

**Which noninvasive test(s) should be used to diagnose NAFLD?**

Worldwide guidelines agree that, whenever NAFLD is suspected, the initial diagnostic workup should include a noninvasive imaging examination to confirm the presence of steatosis and general liver biochemistry[3-8]. Non-invasive assessment should aim first of all to identify NAFLD among patients with metabolic risk factors, and then to monitor disease progression and treatment response, identifying patients with the worst prognosis[3].

**Imaging:** There is a consensus for using abdominal ultrasound (US) as the first-line examination to identify liver steatosis in patients with increased liver blood exams or suspected NAFLD, in daily clinical practice (Figure 2). The main advantages of US derive from its broad availability and low cost. However, its sensitivity among morbidly obese patients (BMI > 40 kg/m²) is low, and it may miss the diagnosis when the liver hepatic fat content is < 20%[15,16]. Despite these limitations, EASL and AISF underline how ultrasound can significantly assess moderate and severe steatosis, even if an observ-

---

**Table 2 Comparative analysis of the recommendations regarding the screening for non-alcoholic fatty liver disease**

| Systematic screening | NICE | Asia-Pacific | AISF | AASLD |
|----------------------|------|--------------|------|-------|
| Screening in high-risk groups | Yes Obesity | Yes Obesity | Yes Obesity | Not mentioned | No |
| Screening modality | Yes liver enzymes | No liver enzymes | Yes ultrasonography | Yes transient elastography | |

---

1Active surveillance’ (but not screening) suggested for patients with type II diabetes mellitus. EASL: European Association for the Study of the Liver; NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the Study of the Liver; AASLD: American Association for the Study of Liver Diseases.
Moreover, laboratory alterations may hide another cause of liver disease, in which steatosis is a coexisting condition. On the other hand, detection of abnormalities of laboratory exams (such as ferritin or autoantibodies) not always reflects the presence of another liver disease, but could be an epiphenomenon of NAFLD with no further clinical significance.

In particular, AASLD guidelines underline that elevated serum ferritin and low titers of autoimmune antibodies (especially antinuclear and anti-smooth muscle antibodies) are common features among NAFLD patients\(^ \text{[18,19]} \), and may not automatically indicate the presence of hemochromatosis or autoimmune liver disease\(^ \text{[8]} \).

Which is the role of diagnostic and prognostic scores?

Noninvasive predictor biomarkers and scores of steatosis and steatohepatitis: The current absence of a highly specific and sensitive noninvasive marker predicting inflammation and fibrosis is leading to a considerable interest in the identification of new markers of disease progression and to the development of clinical scores of disease severity.

To assess the presence of steatosis, EASL, Asia-Pacific, and Italian guidelines mention the Fatty Liver Index (FLI)\(^ \text{[20]} \) and the NAFLD liver fat score\(^ \text{[21]} \). Both of these scores are easily calculated using common blood exams and simple clinical information. In detail, FLI is calculated from serum triglyceride, body mass index, waist circumference, and gamma-glutamyltransferase\(^ \text{[20]} \), while NAFLD liver fat score is calculated evaluating the presence/absence of metabolic syndrome and type 2 diabetes, fasting serum insulin, and aminotransferases\(^ \text{[21]} \). They have been validated in a cohort of severely obese patients and the general population, reliably predicting the presence of steatosis, but not its severity\(^ \text{[22]} \). On the contrary, the AASLD guidelines underline that only inflammation and fibrosis dictate the prognosis of NAFLD patients and, consequently, highlight the lack of evidence.
levels of cytokeratin-18 have good predictive value for effectiveness in identifying patients with advanced fibrosis (ELF) blood test has shown the best cost-benefit ratio among different scores (NAFLD fibrosis score, Fibrometer, Fibrotest, Hepascore) when compared to liver biopsy to confirm advanced fibrosis, and with a negative predictive value of 90% in ruling out cirrhosis when using a cut-off of 7.9 kPa. However, the ability in differentiating between F2 and F3 fibrosis seems less robust. Because of this high rate of false-negative results, EASL guidelines underline that NFS has a stronger negative predictive value for advanced fibrosis than the corresponding positive predictive value. Hence, it should be used for excluding the presence of advanced fibrosis better than stratifying NAFLD patients on different fibrosis stages.

Transient elastography has been recently approved by US Food and Drug Administration to investigate adult and pediatric patients with liver disease. Its cut-off value for advanced fibrosis for adults with NAFLD has been established to 9.9 kPa with 95% sensitivity and 77% specificity. In particular, elastography score has been shown to have good diagnostic accuracy for the presence of clinically significant fibrosis, with an AUROC of 0.93 (95%CI: 0.89-0.96) for advanced fibrosis (F ≥ 3) and cirrhosis, and with a negative predictive value of 90% in ruling out cirrhosis when using a cut-off of 7.9 kPa. However, the ability in differentiating between F2 and F3 fibrosis seems less robust. Because of this high rate of false-positive results, EASL and Asia-Pacific guidelines point out that its low specificity limits its use in daily practice in diagnosing advanced grade of fibrosis and cirrhosis, as well as by a high failure rate.

Moreover considering the unreliable results among patients with high BMI and thoracic fold thickness, EASL guidelines highlight that it should not be used alone as first-line detection tool to identify advanced fibrosis or cirrhosis. In this setting, its poor performance can be improved by using M or XL-probe, increasing the success rate.

American guidelines underline the vital role of magnetic resonance elastography (MRE) in identifying different degrees of fibrosis in patients with NAFLD, performing better than transient elastography for recognizing intermediate stage of fibrosis, but showing a higher predictive value for advanced fibrosis stages. Therefore AASLD guidelines conclude that MRE and transient elastography are both useful tools for identifying NAFLD patients with advanced liver fibrosis.

On the other hand, shear wave elastography, in the same way as transient elastography, seems to be inappropriate to discriminate between intermediate stages of fibrosis and provide reliable results only in 73% of patients with BMI ≥ 30 kg/m².

Which are the best diagnostic algorithms and follow-up strategies?

The optimal strategy for stratifying NAFLD patients and follow disease progression has not been yet established. According to EASL and Italian guidelines, the combination of noninvasive scores (NFS and FIB-4) and transient elastography should be used to identify patients at low risk of advanced liver disease and for clinical decision-making. Moreover, this combination may instead identify patients who should undergo liver biopsy to confirm advanced fibrosis, and in whom a more intensive approach is needed. Noninvasive serum scores should be calculated for every patient with histological proven NAFLD patients in comparison with other scores. EASL guidelines underline that NFS has a stronger negative predictive value for advanced fibrosis than the corresponding positive predictive value. Hence, it should be used for excluding the presence of advanced fibrosis better than stratifying NAFLD patients on different fibrosis stages.

Noninvasive assessment of advanced fibrosis: Liver fibrosis is considered the leading prognostic factor among patients with NAFLD because of its strong correlation with survival rate and liver-related outcomes. Therefore, NAFLD patients with advanced fibrosis need a closer monitoring and a rigorous adherence to treatment. However, to date, no methods easily performed in daily clinical practice and with a high predictive value for differentiating grades of liver fibrosis have been identified.

Different tools have been investigated at this purpose, including noninvasive scores (NAFLD fibrosis score, Fibrosis 4 calculator, AST/ALT ratio index), serum biomarkers (ELF panel, Fibrometer, Fibrotest, Hepascore) and imaging techniques, such as transient elastography, magnetic resonance elastography (MRE) and shear wave elastography.

According to the NICE guideline, the enhanced liver fibrosis (ELF) blood test has shown the best cost-effectiveness in identifying patients with advanced fibrosis stages and therefore should be offered to all patients with an incidental diagnosis of NAFLD. On the other hand, EASL and Italian guidelines suggest the use of NAFLD fibrosis score (NFS) and Fibrosis 4 calculator (FIB-4) as noninvasive scores to identify patients with different risk of advanced fibrosis. These two scores have been validated in various ethnically NAFLD patients, predicting liver and cardiovascular-related mortality. Moreover AASLD guidelines highlight that in a recent study both NFS and FIB-4 have shown the best predictive value for advanced fibrosis among
NAFLD to exclude the presence of significant fibrosis. If it cannot be ruled out, then transient elastography should be performed. Hence, if advanced fibrosis is suspected, liver biopsy should be performed for final diagnosis\(^2,^7\). Moreover, a clinical, laboratory and instrumental follow-up for noninvasive monitoring of fibrosis, is suggested every two years for NAFLD patients with normal liver enzymes and low risk of advanced fibrosis. Patients with evidence of NASH or fibrosis should be screened annually and those with cirrhosis every six months, to perform HCC surveillance\(^2,^7\).

Similarly, the AASLD guidelines consider NFS, FIB-4, transient elastography, and MRE as the first-line examination to detect patients with advanced fibrosis\(^8\). Differently from the EASL guidance, however, no diagnostic algorithms or follow up strategies are provided.

The Asia-Pacific guidelines also agree that combined use of serum tests and imaging tools may offer more reliable information than using either method alone\(^8\). However, they do not specify which noninvasive test is best.

According to the NICE guidelines, every patient with an incidental finding of NAFLD should be screened for advanced fibrosis by ELF blood test. If negative, it should be repeated every three years for adults and two years for children. Moreover, children and young people with type 2 diabetes mellitus or metabolic syndrome, but without steatosis at ultrasound examination, should be reevaluated every three years\(^4\).

Who should undergo liver biopsy?

To date, liver biopsy is the gold standard for diagnosing NASH and staging liver fibrosis, despite several limitations such as sampling error, variability in interpretation by pathologists, high cost and patient discomfort\(^38\). The "NAFLD Activity Score" (NAS)\(^37\) and the "Steatosis Activity Fibrosis" (SAF) scoring system\(^38\) are recommended to assess disease activity\(^8\).

Except for the NICE guidelines (which do not provide specific indications about which patients should undergo liver biopsy), all of the remaining guidelines substantially agree that confirmatory liver biopsy should not be performed in every NAFLD patients. Instead, it should be reserved for the following two situations: (1) Uncertain diagnosis; (2) suspect of NAFLD-related advanced liver disease.

The AASLD guidelines suggest to perform liver biopsy in patients with metabolic syndrome who are at increased risk of liver inflammation, or when NFS, FIB-4 or liver stiffness measured by transient elastography or MRE suggest the presence of advanced liver fibrosis. In that case, patients would benefit the most from diagnosis, obtaining crucial prognostic information\(^8\).

Similarly, EASL and Italian guidelines recommend performing a liver biopsy when both serum and imaging noninvasive tools show a medium/high risk of advanced liver disease, with the aim to confirm the presence of advanced liver fibrosis. Furthermore, they underline that in selected NAFLD patients at high risk of disease progression, the repetition of liver biopsy should be considered case-by-case every five years\(^2,^7\). On the other hand, the Asia-Pacific guidelines recommend biopsy only when a competing aetiology of chronic liver disease cannot be excluded just by laboratory exams and personal anamnesis, or results of noninvasive tests are inconclusive\(^5,^6\).

How to treat NAFLD?

Lifestyle changes: Lifestyle modification consisting of diet, exercise, and weight loss has been advocated to treat patients with NAFLD in all guidelines (Tables 3 and 4). Indeed, weight loss has been reported as a keystone element in improving the histology features of NASH\(^39,^40\).

According to the AASLD position paper\(^7\), the best therapeutic approach is an adequate lifestyle change focused on weight loss and achieved by physical activity (aerobic activities and resistance training) and healthy diet. In particular, an energy restriction obtained with a low calorie (1200-1600 kcal/d), low fat (less than 10% of saturated fatty acid), low carbohydrate diet (< 50% of total kcal) is suggested. A Mediterranean diet is recommended as the most effective dietary option to induce a weight loss together with beneficial effects on all cardio-metabolic risk factors associated with NAFLD\(^7\).

The Asia-Pacific guidelines agree with a lifestyle intervention strategy for the treatment of NAFLD, focusing the attention on the timing of weight loss that should be gradual because of the deleterious effect of crash diets on NASH. Very low-calorie diets are considered unsustainable, and any specific regimen is preferred over the others\(^5\).

Also, the EASL\(^3\), NICE\(^4\), and AASLD\(^5\) guidelines recommend structured programmes aimed at lifestyle changes towards a healthy diet and habitual physical activity. According to all of these guidelines, a 7%-10% weight loss is the target of most lifestyle interventions.

Pharmacological treatment: (1) Who to treat: According to the EASL guidelines\(^3\), pharmacological therapy should be reserved for: Progressive NASH (bridging fibrosis and cirrhosis); early-stage NASH at high risk for disease progression (age > 50 years, metabolic syndrome, diabetes mellitus or increased ALT)\(^41\), active NASH with high necroinflammatory activities\(^42\). Similarly, in the AASLD and Asia-Pacific guidelines, a pharmacological approach is recommended only for patients with NASH and fibrosis\(^8\). In the NICE guidance, just people with an advanced liver fibrosis (ELF test > 10.51) are proposed for pharmacological treatment\(^40\).

In the AASIF position paper, drug therapy is suggested for patients who are at high risk for disease progression\(^7\). (2) Pharmacologic treatment: Currently, no drugs have been approved for the treatment of NASH by the US Food and Drug Administration or by the European Medicines Agency. All guidelines acknowledge that any medicines...
prescribed explicitly for NAFLD should be considered as an off-label treatment and that the decision should be discussed with the patient, carefully balancing the benefits and the safety. However, the guidelines are widely discordant about possibly helpful drugs (Table 5).

Metformin: Due to the evidence of its limited efficacy in improving the histological features of NAFLD[43-45], metformin is not recommended by any guidelines to specifically treat NAFLD[46].

Pioglitazone: Pioglitazone, a thiazolidinedione, is a peroxisome proliferator-activated receptor (PPAR) gamma agonist with insulin-sensitising effects. Treatment with pioglitazone improves insulin sensitivity, aminotransferases, steatosis, inflammation, and ballooning in patients with NASH and prediabetes or T2DM[46]. The PIVENS trial (a large multicenter RCT) compared low dose pioglitazone (30 mg/d) vs vitamin E (800 UI/d) vs placebo for two years in patients without overt diabetes. Pioglitazone improved all histological features (except for fibrosis) and achieved resolution of NASH more often than placebo[47]. The histological benefit occurred together with ALT improvement and partial correction of insulin resistance. The main side effects of glitazones are weight gain[48-51], and bone fractures in women[52].

The use of pioglitazone for the treatment of NAFLD is endorsed both by the NICE and AASLD guidelines, with significant limitations. In the first case, pioglitazone should be prescribed only in second and third level centres, after a careful evaluation[46]. In the latter case, pioglitazone is reserved for patients with biopsy-proven NASH[8]. The EASL guidelines are more cautious, generically suggesting to consider pioglitazone for the treatment of diabetes in patients with a concurrent NAFLD[9]. Even the Asia-Pacific and the Italian guidelines acknowledge the potential benefits of pioglitazone, however, suggest that more evidence should be available before a firm recommendation can be made[6,7].

Vitamin E: Vitamin E is an anti-oxidant and has been investigated to treat NASH. In the PIVENS trial, vitamin E at a dose of 800 IU/d of α-tocopherol for 96 wk was associated with a decrease in serum aminotransferases and histological improvement in steatosis, inflammation,
and ballooning and resolution of steatohepatitis in adults with NASH. Long-term safety of vitamin E is under dispute, with two different meta-analyses leading to conflicting results when analysing the all-cause mortality in patients treated with t doses of > 800 IU/d. Similarly to pioglitazone, vitamin E is recommended by the NICE and AASLD guidelines (limited to biopsy-proven NASH in the latter case). EASL and AISF guidelines call for more evidence before any recommendation, while Asia-Pacific guidelines advice against the use of vitamin E which is described as not beneficial by the current evidence.

Glucagon-like peptide-1 (GLP-1) analogues: Incretin-mimetics, acting on the glucose-insulin interplay have shown favourable results in pre-marketing studies on liver enzymes. Also, in a published randomised, placebo-controlled trial consisting of 52 patients with biopsy-proven NASH, liraglutide administered subcutaneously once-daily for 48 wk was associated with greater resolution of NASH and less progression of fibrosis. Both the AASLD and NICE recommendations state that there is still too few evidence to support the use of GLP-1 analogues to specifically treat liver disease in patients with NAFLD. The remaining guidelines also agree on this point, however also state that further evidence may prove the efficacy of these drugs. In particular, the APASL guidelines consider some more elements in their recommendations. On the one hand, PPAR-agonists appeared to reduce glycated haemoglobin in the latter case. On the other hand, there has been no study on Asian NASH patients, even if the pharmacokinetics of GLP-1 agonists do not appear to differ between Asian and non-Asian patients according to preliminary evidence.

Statins: Historically, the use of statins in patients with chronic liver diseases has been considered as potentially troublesome due to the risk of hepatotoxicity. At the same time, a considerable portion of NAFLD patients usually receives statins because of their multiple cardiovascular risk factors. Consequently, the primary concern of the guidelines is the safety of statins. In this regard, a recent review underlined the safety of statin and their efficacy in reducing the associated cardiovascular morbidity in patients with NAFLD, including those with slightly elevated alanine transaminases (up to 3 × reference upper limit). All of the guidelines agree about the safety of prescribing statins (or continuing an ongoing statin therapy) in patients with NAFLD, even with compensated cirrhosis. However, routine prescription of a statin is not recommended in patients with decompensated cirrhosis and acute liver failure.

Silymarin: Silymarin is a complex mixture of six major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds. In a randomised, double-blinded, placebo-controlled study on patients with biopsy-proven NASH, silymarin dosage of 700 mg three times daily for 48 wk resulted in a significantly higher percentage of fibrosis reduction compared with placebo (22.4% vs 6.0%, $P = 0.023$). The dosage was safe and well tolerated. Silymarin is mentioned as a potentially useful treatment for NASH in Asia-Pacific guidelines only. However, optimal dose and duration still require further studies before a full recommendation.

### Table 5: Recommendations about pharmacological treatment of non-alcoholic fatty liver disease

| EASL | NICE | ASIA-PACIFIC | AISF | AASLD |
|------|------|--------------|------|-------|
| Metformin | Insufficient evidence | Not beneficial | Not beneficial | Not mentioned | Not beneficial |
| Vitamin E | Insufficient evidence | Not beneficial | Insufficient evidence | Insufficient evidence | Consider use in non-diabetic, biopsy-proven NASH |
| PPAR-gamma agonists | Consider use in selected diabetic patients | Consider pioglitazone in adults regardless of diabetes | Insufficient evidence in Asian patients | Insufficient evidence in potentially useful | Pioglitazone indicated in biopsy-proven NASH (regardless of diabetes) |
| PUFAs | Not beneficial | Insufficient evidence | Not beneficial | Not mentioned | Not beneficial |
| Pentoxifylline | Insufficient evidence | Insufficient evidence | Insufficient evidence | Insufficient evidence in potentially useful | Insufficient evidence |
| GLP-1 analogues | Insufficient evidence, potentially useful | Insufficient evidence | Insufficient evidence | Insufficient evidence | Insufficient evidence |
| UDCA | Not beneficial | Not mentioned | Not mentioned | Not mentioned | Not beneficial |
| Obettycolic acid | Scarce evidence | Not mentioned | Waiting for ongoing RCT results | Waiting for ongoing RCT results | Insufficient evidence |
| Silymarin | Not mentioned | Not mentioned | Insufficient evidence, potentially useful | Not mentioned | Not mentioned |
| Statins | Safe but not beneficial | Safe but not beneficial | Safe but not beneficial | Safe but not beneficial | Safe but not beneficial |

EASL: European Association for the Study of the Liver; NICE: National Institute for Health and Care Excellence; AISF: Italian Association for the Study of the Liver; AASLD: American Association for the Study of Liver Diseases; PPAR: Peroxisome proliferator-activated receptors; PUFAs: Poly-unsaturated fatty acids; GLP-1: Glucagon-like peptide-1.
of established cirrhosis is associated with peri-operative risks. In particular, in the analysis performed from the Nationwide Inpatient Sample (1998-2007), mortality was higher in patients with compensated cirrhosis (0.9%) and much higher in those with decompensated cirrhosis (16.3%)[60]. No robust data on the comparative effects of different bariatric procedures on liver fat are available in the literature.

Based on the evidence as mentioned earlier, the EASL guidelines consider bariatric surgery an option in patients unresponsive to lifestyle changes and pharmacotherapy, for reducing weight and metabolic complications[3]. Guidance statements by the AASLD also consider a role of foregut bariatric surgery in otherwise eligible obese individuals with NAFLD or NASH[8].

The Asia-Pacific recommendation limits the role of bariatric surgery only to patients with class II obesity (BMI > 32.5 kg/m2 in Asians and 35 kg/m2 in Caucasians)[62]. AISF and NICE guidelines do not mention bariatric surgery.

Liver transplantation: NASH is becoming the most common indication to liver transplantation in Western Countries[57]. Because of the high prevalence of obesity, sarcopenia, cardiovascular disease and chronic kidney disease among patients with NASH, there is a higher frequency of post-transplant complications and increased graft loss[68,69]. Because of the risk of prolonged ventilation, poor wound healing, higher rate of primary graft non-function, and increased infectious complications, patients with severe obesity (BMI > 40 kg/m2) may even be considered unfit for liver transplantation, unless efforts are made preoperatively to reduce body weight with individualized plans of lifestyle modifications[20].

AISF and NICE guidance do not mention liver transplantation. All of the remaining guidelines agree that liver transplantation is an acceptable procedure in NASH patients with an end-stage liver disease, with the same indications adopted for other etiologies of liver disease[3,48].

CONCLUSION

The comparative analysis of the most recent international guidelines for the management of NAFLD showed some common orientation between the different recommendations, as well as diverging points. The most notable differences involved: the identification of the alcohol threshold defining NAFLD, the screening strategies in high-risk populations, the preferred non-invasive biomarkers for the assessment of advanced fibrosis, and the pharmacological treatment. These differences should not be necessarily seen as a limitation, but rather an expression of the geographical differences in genetic predisposition to NAFLD, lifestyle habits, healthcare systems. Arguably, the similarity in the recommendations could greatly help in ensuring homogenous management of NAFLD all over the world, with favourable repercussions both in clinical practice and in clinical trials. In the next years, we might see a trend toward more homogenous guidelines thanks to the increasing body of evidence. In particular, the advancements in the imaging technologies could lead to new and widely accepted noninvasive methods to assess advanced liver fibrosis. Moreover, some clinical trials are investigating potentially effective drugs. If positive, the currently diverging pharmacological recommendations may reach a higher concordance. NAFLD is becoming a leading field of research in hepatology: new evidence is destined to change the current landscape of knowledge, prompting greater benefits to the patients as well as changes in the recommendations for clinical practice.

REFERENCES

1 De Minicis S, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights. Curr Pharm Des 2013; 19: 5239-5249 [PMID: 23394093 DOI: 10.2174/1381180039000661]
2 Schwimmer JB, Deutsch R, Kahn T, Lavine JE, Stanley C, Buhling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393 [PMID: 17015527 DOI: 10.1542/peds.2006-1212]
3 European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]
4 National Institute for Health and Care Excellence (UK). Non-Alcoholic Fatty Liver Disease: Assessment and Management. Available from: URL: http://www.nice.org.uk/guidance/ng9
5 Wong VW, Chan WK, Chitini S, Chawla Y, Dan YY, Dusea A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SK, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol 2018; 33: 70-85 [PMID: 28670712 DOI: 10.1111/jgh.13857]
6 Chituri S, Wong VW, Chan WK, Wong GL, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, Kim SK, Hashimoto E, Hamaguchi M, Goh KL, Fan J, Dusea A, Dan YY, Chawla Y, Farrell G, Chan HL. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol 2018; 33: 86-98 [PMID: 28692197 DOI: 10.1111/jgh.13856]
7 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis 2017; 49: 471-483 [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147]
8 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brent EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357 [PMID: 28714183 DOI: 10.1002/hep.29367]
9 Paradis V, Zalinski S, Chelbi E, Gueld N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859 [PMID: 19153777 DOI: 10.1002/hep.22734]
10 Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marrelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838 [PMID: 26599251 DOI: 10.1002/hep.28368]
11 Portillo-Sanchez P, Brill F, Maximos M, Lomonaco R, Biernacki D,
non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther 2012; 36: 1057-1066 [PMID: 23066964 DOI: 10.1111/apt.12091]

25 Chan WK, Sthaneswar P, Ntk Mustapa NR, Mahadeva S. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers. PLoS One 2014; 9: e105903 [PMID: 25184298 DOI: 10.1371/journal.pone.0105903]

26 Vuppulanchi R, Jain AK, Deppe R, Yates K, Cornford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brun EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tomascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2121-2130. e1-2 [PMID: 24884629 DOI: 10.1016/j.clg.2014.05.010]

27 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554 [PMID: 25120770 DOI: 10.1002/hep.27368]

28 Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci 2016; 61: 1361-1364 [PMID: 27017224 DOI: 10.1007/s10620-016-4079-4]

29 Fagan KJ, Pretorius CJ, Horsfall LU, Irvine KM, Wilgen U, Choi K, Fletcher LM, Tate J, Melino M, Nusrat S, Miller GC, Clouston AD, Ballard E, O’Rourke P, Lampe G, Ungerer JP, Powell EE. ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int 2015; 35: 1673-1681 [PMID: 25495373 DOI: 10.1111/liv.12760]

30 Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460 [PMID: 18038452 DOI: 10.1002/hep.21984]

31 Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2016; 111: 677-684 [PMID: 26977758 DOI: 10.1038/ajg.2016.49]

32 Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chernak F, Choi PC, Merrouche W, Chu SH, Pesque S, Chan HL, de Lédinghen V. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2012; 27: 1862-1871 [PMID: 23032979 DOI: 10.1111/j.1440-1746.2012.06758.x]

33 Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kewo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462 [PMID: 20101745 DOI: 10.1002/hep.23312]

34 Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Echigi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 2016; 150: 626-637.e7 [PMID: 26677985 DOI: 10.1053/j.gastro.2015.11.048]

35 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol 2017; 5: 261-271 [PMID: 28936407 DOI: 10.14288/JCTH.2017.00009]

36 Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13 [PMID: 22418883 DOI: 10.1055/s-0032-1306421]

37 Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759 [PMID: 22707395 DOI: 10.1002/hep.25889]
Bedossa P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAFE) score in the evaluation of biopsies of nonalcoholic fatty liver disease. *Hepatology* 2014; 60: 565-575 [PMID: 24753132 DOI: 10.1002/hep.27173]

Haufe S, Englert S, Kast P, Böhnke J, Utz W, Haas V, Hermdsdorf M, Mähler A, Wiesner S, Birkenfeld AL, Soll H, Otto C, Mehlng H, Lu F, Eckel J, Schulz-Menger J, Boschmann M, Jordan J. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrapathic fat in overweight and obese human subjects. *Hepatology* 2011; 53: 1504-1514 [PMID: 21400557 DOI: 10.1002/hep.24242]

Astrich M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. *Clin Naur 2014; 33: 186-190 [PMID: 24262589 DOI: 10.1016/j.cml.2013.11.003]*

Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatology* 2005; 42: 132-138 [PMID: 15629518 DOI: 10.1016/j.jhep.2004.09.012]

Sanayi AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases, United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. *Hepatology* 2015; 61: 1392-1405 [PMID: 25557690 DOI: 10.1002/hep.27678]

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzizzo M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or placebo diet in nonalcoholic fatty liver disease. *Am J Gastroenterol* 2005; 100: 1082-1090 [PMID: 15842582 DOI: 10.1111/j.1572-0241.2004.41583.x]

Haukeland JW, Konopski Z, Eggesbo HB, von Vollmkn HL, Raschpichler G, Bjørk O, Haaland T, Leber EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. *Scand J Gastroenterol* 2009; 44: 853-860 [PMID: 19811343 DOI: 10.1080/00365520902845268]

Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. *Therap Adv Gastroenterol* 2009; 2: 157-163 [PMID: 21180541 DOI: 10.1177/1756283X09010546]

Belfort R, Harrison SA, Brown K, Durlach C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the Hba1c-lowering efficacy of glucagon-like peptide-1 analogues between and non-asians: A systematic review and meta-analysis. *Diabetes Obes Metabol* 2014; 16: 900-909 [PMID: 24655583 DOI: 10.1111/dob.12293]

Cui Y, Guo GX, Zhang DM, Tham LS, Tang CC, Mace K, Linnebjerg H. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. *J Diabetes* 2013; 5: 127-135 [PMID: 23332026 DOI: 10.1111/j.1753-0407.12020]

Ingwersen SH, Petri KC, Tandon N, Yoon KH, Chen L, Vora J, Yang W. Linagliptin pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea. *Diabetes Res Clin Pract* 2015; 108: 113-119 [PMID: 25684604 DOI: 10.1016/j.diabres.2015.10.001]

Cohen DE, Anania FA, Chalasani N; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. *Am J Cardiol* 2006; 97: 77C-81C [PMID: 16581333 DOI: 10.1016/j.amjcard.2005.12.014]

Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. *Dig Dis Sci* 2014; 59: 1958-1965 [PMID: 24838495 DOI: 10.1007/s10620-014-3179-2]

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McFride P, Schwartz JS, Sher ST, Smith SC Jr, Watson K, Wilson PW, Faden R, Schenker GA, Schenker KM, Jarrett RM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohrman E, Pressler SJ, Selleck FW, Shen WK, Smith SC Jr, Tomalini GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014; 129: S1-S45 [PMID: 24222061 DOI: 10.1161/01.CIR.0000473778.6835.7a]

Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silibum marianum) for the therapy of liver disease. *Am J Gastroenterol* 1998; 93: 139-143 [PMID: 9468229 DOI: 10.1111/j.1572-0241.1998.00139.x]

Wah Kheong C, Nik Mustapha NR, Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. *Clin Gastroenterol Hepatol* 2017; 15: 1940-1949 [PMID: 28419855 DOI: 10.1016/j.cgh.2017.04.016]

Schafer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR; STAMPEDE Investigators. Bariatric surgery versus pharmacological therapy alone in patients with type 2 diabetes mellitus: a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2014; 387: 679-690 [PMID: 25602526 DOI: 10.1016/S0140-6736(15)00803-X]

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurt JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Linagliptin safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *BMJ* 2012; 344: d7771 [PMID: 22236411 DOI: 10.1136/bmj.d7771]

Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005; 142: 37-46 [PMID: 15537682 DOI: 10.7326/0003-4819-142-1-200501040-00007]

Abner EI, Schmirt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. *Curr Aging Sci* 2011; 4: 158-170 [PMID: 21235492 DOI: 10.2174/18746981110140518]

Vilsboll T, Christensen M, Junker AE, Knop FK, Glaud IL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ* 2012; 344: d7771 [PMID: 22236411 DOI: 10.1136/bmj.d7771]

Linnebjerg H. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. *J Diabetes* 2013; 5: 127-135 [PMID: 23332026 DOI: 10.1111/j.1753-0407.12020]
Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Ciaazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, Romon M, Pattou F. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. *Gastroenterology* 2009; 137: 532-540 [PMID: 19409989 DOI: 10.1053/j.gastro.2009.04.052]

Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. *Gastroenterology* 2015; 149: 379-388; quiz e15-16 [PMID: 25917783 DOI: 10.1053/j.gastro.2015.04.014]

Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. *Obes Surg* 2015; 25: 2280-2289 [PMID: 25917981 DOI: 10.1007/s11695-015-1691-x]

Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. *Gastroenterology* 2011; 141: 1249-1253 [PMID: 21726509 DOI: 10.1053/j.gastro.2011.06.061]

Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. *Hepatology* 2002; 35: 105-109 [PMID: 11786965 DOI: 10.1053/jhep.2002.30318]

Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, Esfandiari N, Baracos V, Montano-Loza AJ, Myers RP. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. *Liver Transpl* 2012; 18: 1209-1216 [PMID: 22740290 DOI: 10.1002/lt.23495]

Hakeem AR, Cockbain AJ, Raza SS, Pollard SG, Toogood GJ, Atia MA, Ahmad N, Hidalgo EL, Prasad KR, Menon KV. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. *Liver Transpl* 2013; 19: 551-562 [PMID: 23408499 DOI: 10.1002/lt.23618]